Synopsis
Calcium Phosphate solubility curves are published for TrophAmine® and PremaSol® by their respective manufacturers. Such solubility curves must be used for any clinical decisions in making formulation determinations for the specific drug product being utilized. Oversight and regulatory bodies, such as local Boards of Pharmacy, Centers for Medicare & Medicaid Services (CMS) and The Joint Commission (TJC) typically rely on the manufacturer’s technical and prescribing information when accessing the appropriateness of the use of the drug and its dosing in patient care. The clinician compounding the parenteral nutrition should not deviate from the manufacturer’s published prescribing information. Experience and professional judgment guide the use of these agents toward the desired patient outcome. The use of Calcium Phosphate solubility curves not specific to the drug product you are actually using is not consistent with good clinical practice and most likely outside the product’s liability limits in the event of any adverse drug events.
